obesity drug news today glp-1 oct 27 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Weight loss with GLP-1 medicines

The human dopamine transporter (hDAT) contains a high-affinity, extracellular, and allosteric Zn 2+ (zinc ion) binding site which, upon zinc binding, inhibits dopamine reuptake, inhibits amphetamine-induced hDAT internalization, and amplifies amphetamine-induced dopamine efflux

2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial

Water-soluble peptide components inhibit tyrosinase activity, which creates melanin pigment

Your face gets all the attention but your body deserves the same science

Glucose-dependent insulinotropic polypeptide signaling in pancreatic -cells and adipocytes